ArticleScience advances2026
Dual-mode microfluidic immunostaining device for diagnostic biomarkers detection and tumor microenvironment evaluation.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multi-channel automated programmable liquid exchange system enables high-quality sample preparation for super-resolution microscopy.Innovation (Cambridge (Mass.)) · 2026Article
- Article
- Remote-Controlled Microfluidic Platform for Real-Time Detection of Multiple Mycotoxins on Chip.Foods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The limited availability of tissue samples from rare tumors poses a major barrier to advances in precise diagnosis, prognostic evaluation, and therapeutic research-challenges exemplified by primary central nervous system diffuse large B cell lymphoma (PCNS-DLBCL). Here, we developed a dual-mode microfluidic immunostaining (Dumi) device, which integrates diagnostic and research workflows into a single, automated platform, reducing tissue section consumption by more than 90%. Using just one to two slides, it enables both regional detection of biomarkers for diagnostic subtyping (≤16) and construction of multiplex tumor microenvironment (TME) maps. Joint analysis of multiregion diagnostic biomarkers in the TME map indicates that tumor cell subpopulations defined by specific diagnostic biomarkers can actively shape their in situ microenvironmental niche. Dumi offers an efficient, cost-effective, and multifunctional immunostaining method, overcoming the limitations of scarce tissue resources and providing a clinically accessible solution to the diagnostic and therapeutic challenges with rare tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.